Conner Strong & Buckelew Announces First-of-Its-Kind Insurance Program for Cell & Gene Therapy Product Shortages

New Insurance Endorsement Addresses Product Shortages

Conner Strong & Buckelew has introduced a new insurance endorsement called the New Product Shortage PLUS Endorsement. This product aims to fill a key coverage gap concerning injury-related claims that arise from product unavailability or delivery failures, particularly in the cell and gene therapy sectors.

Who Is Affected?

This endorsement is designed for businesses involved in cell and gene therapy, where timely access to products is crucial for treatment and patient care. With an increasing demand for these therapies, the potential for supply chain issues can lead to significant liability concerns. The New Product Shortage PLUS Endorsement addresses these risks by providing coverage when certain products are unavailable, ensuring that companies are better protected against possible claims related to patient harm or delays.

Key Features of the New Endorsement

Some notable aspects of this new endorsement include:

• Specifically Tailored Coverage: It is crafted to meet the unique needs of the cell and gene therapy market.
• Injury-Related Claims Protection: Offers support for claims that may arise when products cannot be delivered or are in short supply.
• Risk Mitigation: Aims to reduce potential financial impact on businesses due to unforeseen product shortages.

Importance for the Industry

This new offering highlights the evolving nature of insurance solutions in response to the complexities of modern healthcare and supply chains. As companies face increasing pressures from both consumers and regulators, the endorsement provides a proactive measure to manage risk effectively.

As indicated by the official announcement, this initiative reflects a growing recognition of the unique challenges faced by those in the biotech and pharmaceutical fields. Companies that opt for this coverage may find themselves better equipped to navigate the uncertain landscape of product availability.

Original Source: https://www.globenewswire.com/news-release/2025/11/03/3179201/0/en/Conner-Strong-Buckelew-Announces-First-of-Its-Kind-Insurance-Program-for-Cell-Gene-Therapy-Product-Shortages.html